Neuroscience

Axsome Therapeutics Presents Data from Multiple Programs Spanning Its Innovative Neuroscience Portfolio at Psych Congress 2024

NEW YORK, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel…

1 year ago

Neumora Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024

WATERTOWN, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics…

1 year ago

Linus Health to Demonstrate How Digital Health Powers Innovation at Clinical Trials on Alzheimer’s Disease (CTAD)

Leaders to deliver four poster presentations showing how its digital health platform lowers investigator burden, enables precision recruitment, and delivers…

1 year ago

MIRA Pharmaceuticals’ Ketamir-2 Shows 60% Greater Efficacy Than FDA-Approved Gabapentin in Reversing Chemotherapy-Induced Neuropathic Pain

Promising Preclinical Results Position Ketamir-2 as a Potential Breakthrough Therapy That Surpasses Current Treatments, With Results to Be Presented at…

1 year ago

Firefly Neuroscience Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

TORONTO, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”)…

1 year ago

Vitamin K supplement slows prostate cancer in mice

COLD SPRING HARBOR, N.Y., Oct. 24, 2024 /PRNewswire/ -- Prostate cancer is a quiet killer. In most men, it's treatable.…

1 year ago

Lin Health to Collaborate with Mayo Clinic to Expand Access to Evidence-Based, Tech-Enabled Chronic Pain Care

Retraining the brain's neural circuitry through a behavioral health approach empowers people living with chronic pain to avoid costly and…

1 year ago

MIRA Pharmaceuticals Announces Ketamir-2 Outperforms Current FDA-Approved Neuropathic Pain Treatments, Gabapentin and Pregabalin, in Preclinical Study

MIAMI, FL / ACCESSWIRE / October 21, 2024 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a leading pre-clinical-stage pharmaceutical development company, is…

1 year ago

Supernus Announces Promising Data from Open-Label Phase 2a Study of SPN-820 in Adults with Major Depressive Disorder

Phase 2a study demonstrated rapid and substantial decrease in depressive symptoms SPN-820 was well-tolerated with few adverse events SPN-820 is…

1 year ago

Nikon Small World Competition Celebrates 50 Years with Groundbreaking Image of Brain Tumor Cells

Celebrating its golden anniversary, Nikon Small World honors a stunning photo of brain tumor cell structures, advancing our understanding of…

1 year ago